Article Figures & Data
Figures
- Figure 1
TASTE-2 study design. EVT, endovascular therapy; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; TASTE-2, Treatment of Acute Ischaemic Stroke with Edaravone Dexborneol II.
- Figure 2
The inclusion and exclusion criteria of the TASTE-2 trial. TASTE-2, Treatment of Acute Ischaemic Stroke with Edaravone Dexborneol II.
Tables
- Table 1
The assessment flow chart
Procedure/investigation Baseline Follow-up 1 Follow-up 2 Follow-up 3 Follow-up 4 Before randomisation The day of randomisation 1st day after randomisation (24±12 hours） 14th day after randomisation or at discharge* 90±7th day after randomisation Acquiring informed consent x Demographic information x Medical history x Prior medication x Physical examination x x x x NIHSS x x x mRS X† x x ECG x Laboratory test X‡ Urine pregnancy test x Non-contrast CT/DWI (ADC) x x CTA/MRA/DSA x§ CTP/MRP x¶ Inclusion/exclusion criteria check x Randomisation x Blood sample x x Drug delivery x** EVT x Medication adherence x AE/SAE x x x x Concomitant medication x x *If patient has not been discharged on the 14th day after randomisation, record the information on day 14th, if discharged before the day, record the information on the day of discharge. The interventional drug treatment duration is at least 10 days, so the discharge day should not be earlier than the 10th day after randomisation.
†Indicates the prior stroke modified Rankin Scale.
‡Includes blood routine test, blood biochemistry (at least ALT, AST, serum creatinine/estimated glomerular filtration rate, fast glucose, electrolytes) and coagulation profile.
§At least one categories of angiography (CTA or MRA or DSA) was performed at baseline to certify the location of large vessel occlusion in the anterior circulation.
¶For patients within 6–16 hours of symptom onset, the baseline screening image should contain CT+CTA+CTP or DWI+ADC+MRA+MRP (based on the DEFUSE-3 criteria: an infarct core <70 mL, a mismatch volume >15 mL and a mismatch ratio >1.8). For those within 16–24 hours of symptom onset, it should contain CT+CTA+CTP, or DWI+ADC+MRA (based on the DAWN criteria: an NIHSS score ≥10 with an infarct core volume <31 cm3, or an NIHSS score ≥20 with an infarct core volume ≤51 cm3). CT perfusion or MR diffusion and perfusion scans were evaluated by using an automatic software.
**Interventional drugs should be delivered after randomisation but ahead of EVT.
ADC, apparent diffusion coefficient; AE, adverse event; ALT, alanine aminotransferase; AST, aspartate transaminase; CTA, CT angiography; CTP, CT perfusion; DSA, digital subtraction angiography; DWI, diffusion-weighted imaging; EVT, endovascular therapy; MRA, MR angiography; MRP, MR perfusion; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; SAE, serious AE.
